Trial Site News
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
  • Register
  • Log In
  • News
  • Video
  • Podcast
  • More
Trial Site News
  • News For You
  • Podcast
  • New for You
  • Covid-19
  • Video
  • Podcast

Search Results for janssen

BARDA-Supported Johnson & Johnson Unit Janssen COVID-19 Vaccine Candidate Gets Closer: Requiring Only 1 Dose & Potential EUA Request May Occur by Feb

TrialSite predicted months ago that the vaccine, sponsored by the world’s largest pharmaceutical company by revenue–Johnson & Johnson, could become […]

BARDA-Supported Johnson & Johnson Unit Janssen COVID-19 Vaccine Candidate Gets Closer: Requiring Only 1 Dose & Potential EUA Request May Occur by Feb
4 days ago
Share
0

St. Jude Children’s Research Hospital & Univ. of TN Health & Science Center Recruit Volunteers for ENSEMBLE Trial: COVID-19 Vaccine from Janssen

St. Jude Children’s Research Hospital and the University of Tennessee Health Science Center (UTHSC) now offer a testing site for […]

St. Jude Children’s Research Hospital & Univ. of TN Health & Science Center Recruit Volunteers for ENSEMBLE Trial: COVID-19 Vaccine from Janssen
2 months ago
Share
0

Helen Joseph Hospital’s CHRU Hosts Janssen Pharmaceutical ENSEMBLE COVID-19 Vaccine Trial in South Africa

Johannesburg’s Helen Joseph Hospital was selected by Janssen Pharmaceutical Companies of Johnson & Johnson as a trial site organization for […]

Helen Joseph Hospital’s CHRU Hosts Janssen Pharmaceutical ENSEMBLE COVID-19 Vaccine Trial in South Africa
2 months ago
Share
0

Sema4 Gives Janssen Access to Potential Competitive Advantage in Recruiting Oncology Patients

Janssen Research & Development, LLC (Janssen), a part of Johnson & Johnson, inked a partnership with a patient-centered health intelligence […]

Sema4 Gives Janssen Access to Potential Competitive Advantage in Recruiting Oncology Patients
4 months ago
Share
0

UK Government Secures 90 Million doses of COVID-19 Vaccine from Janssen & Novavax

The government of the United Kingdom reported in a press release that it has secured early access to 90 million […]

UK Government Secures 90 Million doses of COVID-19 Vaccine from Janssen & Novavax
5 months ago
Share
0

Aleafia Health Approved by Janssen Pharmaceuticals to Administer Antidepressant SPRAVATO®

SPRAVATO® (esketamine) nasal spray uses the first new mechanism of action in decades to treat treatment resistant depression disorder  Aleafia Health medical clinics […]

6 months ago
Share
0

Janssen Pharmaceuticals Discontinues Phase 3 LOTUS Study of Ustekinumab Due to Lack of Efficacy in Patients with SLE

Janssen Pharmaceuticals announced the phase 3 LOTUS study, evaluating Stelara (ustekinumab) in patients with Systemic Lupus Erythematosus (SLE) will be […]

Janssen Pharmaceuticals Discontinues Phase 3 LOTUS Study of Ustekinumab Due to Lack of Efficacy in Patients with SLE
7 months ago
Share
0

J&J (Janssen) Picks up Speed with Ad26.COV2-S COVID-19 Vaccine: A Giant is in the Race

Johnson & Johnson (NYSE: JNJ) (the Company) today announced that through its Janssen Pharmaceutical Companies (Janssen) it has accelerated the […]

J&J (Janssen) Picks up Speed with Ad26.COV2-S COVID-19 Vaccine A Giant is in the Race
7 months ago
Share
0

J&J (Janssen) R&D Externalization Engine with Beth Israel Deaconess Medical Center Turned on to Target COVID-19

Beth Israel Deaconess Medical Center (BIDMC) inked a collaborative deal with Johnson & Johnson’s Janssen Pharmaceutical Co to develop a […]

J&J (Janssen) R&D Externalization Engine with Beth Israel Deaconess Medical Center Turned on to Target COVID-19
10 months ago
Share
0

Janssen Announces U.S. FDA Has Granted Breakthrough Therapy Designation to JNJ-6372 for Metastatic Non-Small Cell Lung Cancer

Janssen announced the U.S. Food and Drug Administration (FDA) granted JNJ-6372 Breakthrough Therapy Designation for metastatic non-small cell lung cancer […]

Janssen Announces U.S. FDA Has Granted Breakthrough Therapy Designation to JNJ-6372 for Metastatic Non-Small Cell Lung Cancer
10 months ago
Share
0

Posts navigation

Older posts

Trending News

  • Not Using Ivermectin, One Year In, Is Unethical And Immoral
    Not Using Ivermectin, One Year In, Is Unethical And Immoral
  • New York Supreme Court Judge Order: Give The Patient Ivermectin As Court Battle Leads to Ivermectin for Successful Treatment Against COVID-19
    New York Supreme Court Judge Order: Give The Patient Ivermectin As Court Battle Leads to Ivermectin for Successful Treatment Against COVID-19
  • An Unlikely Nation Is Kicking This Pandemic. Guess Which. Then Why.
    An Unlikely Nation Is Kicking This Pandemic. Guess Which. Then Why.
  • In Far-Flung Places, COVID-19 Is Being Treated Early And Well. Here’s Why Americans Don’t Know This.
    In Far-Flung Places, COVID-19 Is Being Treated Early And Well. Here’s Why Americans Don’t Know This.
  • Growing Momentum for Ivermectin in German Press as Pharmacy Journal Introduces Ivermectin as Possible Treatment for COVID-19
    Growing Momentum for Ivermectin in German Press as Pharmacy Journal Introduces Ivermectin as Possible Treatment for COVID-19

Latest Podcasts

Alan Cannell talks COVID-19: Nobody Likes Cheap Solutions | Podcast S2 E41

Dr. Pierre Kory Talks Covid-19, Ivermectin and the FLCCC | Podcast E43

An Interview With Patricia Carter: Patient Engagement and Retention in Clinical Trials

Dr. Negin Hajizadeh: Researchers Finding A Very Effective Treatment For Covid-19 In New Study

Dr. Jean-Jacques Rajter and Dr. Juliana Cepelowicz Rajter Discuss Ivermectin In Broward County | Podcast S2 E 27

159 W Broadway, Suite 200
Salt Lake City, UT 84101

[email protected]

Connect With Us

TRIALSITE NEWS IS THE ONLY DIGITAL MEDIA DEDICATED 100% TO TRANSPARENT AND OPEN COVERAGE OF CLINICAL RESEARCH TRIAL SITES AROUND THE GLOBE. BASED IN THE SILICON SLOPES IN DOWNTOWN SALT LAKE CITY, UTAH, WE ARE FOUNDED BY A TEAM OF EXPERTS IN THE CLINICAL TRIALS INDUSTRY AND DEDICATED TO TRANSPARENCY, QUALITY AND CLINICAL TRIAL INNOVATION.

© 2021 TRIALSITE NEWS. ALL RIGHTS RESERVED.